PLx Pharma Inc. - Product Pipeline Review - 2012

Global Markets Direct, June 2012, Pages: 39

PLx Pharma Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “PLx Pharma Inc. - Product Pipeline Review - 2012” provides data on the PLx Pharma Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, PLx Pharma Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from PLx Pharma Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- PLx Pharma Inc. - Brief PLx Pharma Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of PLx Pharma Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of PLx Pharma Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the PLx Pharma Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate PLx Pharma Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of PLx Pharma Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the PLx Pharma Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with PLx Pharma Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of PLx Pharma Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of PLx Pharma Inc.; PLx Pharma Inc. - Key Therapeutics; PLx Pharma Inc. - Pipeline Overview and Promising Molecules; PLx Pharma Inc. - News; PLx Pharma Inc. - Latest Updates; PLx Pharma Inc. - Pipeline; PLx Pharma Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
PLx Pharma Inc. Snapshot
PLx Pharma Inc. Overview
Key Information
Key Facts
PLx Pharma Inc. – Research and Development Overview
Key Therapeutic Areas
PLx Pharma Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
PLx Pharma Inc. – Pipeline Products Glance
PLx Pharma Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
PLx Pharma Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
PLx Pharma Inc. – Drug Profiles
Diclofenac PC
Product Description
Mechanism of Action
R&D Progress
Ketorolac
Product Description
Mechanism of Action
R&D Progress
Meloxicam
Product Description
Mechanism of Action
R&D Progress
Piroxicam
Product Description
Mechanism of Action
R&D Progress
PL 1100 Ibuprofen
Product Description
Mechanism of Action
R&D Progress
PL 1200 Ibuprofen-PC
Product Description
Mechanism of Action
R&D Progress
PL 2200 Aspirin
Product Description
Mechanism of Action
R&D Progress
PL 4100 Indomethacin
Product Description
Mechanism of Action
R&D Progress
PL 4500 Indomethacin-PC
Product Description
Mechanism of Action
R&D Progress
PL 5100 Diclofenac
Product Description
Mechanism of Action
R&D Progress
PLx Pharma Inc. – Pipeline Analysis
PLx Pharma Inc. – Pipeline Products by Therapeutic Class
PLx Pharma Inc. – Pipeline Products by Route of Administration
PLx Pharma Inc. – Pipeline Products By Mechanism of Action
PLx Pharma Inc. – Recent Pipeline Updates
PLx Pharma Inc. - Dormant Projects
PLx Pharma Inc. – Locations And Subsidiaries
Head Office
PLx Pharma Inc., Recent Developments
PLx Pharma Inc.- Press Release
May 22, 2012: PLx Pharma Files New Drug Application For PL2200 Aspirin With FDA
Mar 28, 2012: PLx Pharma Receives $565,449 Grant For Research On Congenital Heart Defect In Premature Babies
Feb 06, 2009: PLx Receives $0.73 Million In Funding From US Army In SBIR Phase II Award
Financial Deals Landscape
PLx Pharma Inc., Deals Summary
PLx Pharma Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
PLx Pharma Secures $2.9 Million In Series F Round
PLx Pharma Secures $2 Million In Venture Financing
PLx Pharma Secures $4.1 Million In Financing
Licensing Agreements
PLx Pharma Enters Into Licensing Agreement With Lee's Pharma For Cardiovascular Product
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
PLx Pharma Inc., Key Information
PLx Pharma Inc., Key Facts
PLx Pharma Inc. – Pipeline by Indication, 2012
PLx Pharma Inc. – Pipeline by Stage of Development, 2012
PLx Pharma Inc. – Monotherapy Products in Pipeline, 2012
PLx Pharma Inc. – Phase II, 2012
PLx Pharma Inc. – Pre-Clinical, 2012
PLx Pharma Inc. – Pipeline By Therapeutic Class, 2012
PLx Pharma Inc. – Pipeline By Route of Administration, 2012
PLx Pharma Inc. – Pipeline Products By Mechanism of Action, 2012
PLx Pharma Inc. – Recent Pipeline Updates, 2012
PLx Pharma Inc. - Dormant Developmental Projects,2012
PLx Pharma Inc., Deals Summary
PLx Pharma Secures $2.9 Million In Series F Round
PLx Pharma Secures $2 Million In Venture Financing
PLx Pharma Secures $4.1 Million In Financing
PLx Pharma Enters Into Licensing Agreement With Lee's Pharma For Cardiovascular Product

List of Figures
PLx Pharma Inc. – Pipeline by Indication, 2012
PLx Pharma Inc. – Pipeline by Stage of Development, 2012
PLx Pharma Inc. – Monotherapy Products in Pipeline, 2012
PLx Pharma Inc. – Pipeline By Therapeutic Class, 2012
PLx Pharma Inc. – Pipeline By Route of Administration, 2012
PLx Pharma Inc. - Pipeline Products By Mechanism of Action, 2012

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• eBay - Strong Execution
• Scientific Games Corporation - Company Analysis
• Amazon - Point of Realization in 2013?
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Ixia - Company Analysis
• SunGard - Profile - US
• Insight into Samsung Electronics' Notebook PC Business Model
• US - Accenture - Company Profile